Zylox-Tonbridge Medical Technology Co., Ltd.

Zylox-Tonbridge Medical Technology Co., Ltd. is a China-based medical device company focused on the research, development, manufacturing, and commercialization of minimally invasive interventional devices for neurovascular and peripheral vascular diseases. The company is headquartered in Hangzhou, Zhejiang Province, and positions itself as an international medical device group serving both the Chinese market and overseas markets. Its product portfolio is organized around two core therapeutic areas: neurovascular interventions and vascular interventions, covering conditions such as stroke, peripheral artery disease, and hemodialysis access dysfunction. The company's official website describes it as a "Revascularization Device, International Medical Device Company," and its product and education sections cover a wide range of interventional technologies, including stent retrievers, thrombectomy stents, PTA balloon catheters, atherectomy devices, inferior vena cava (IVC) filters, and vascular stents. Among the products highlighted on its site are the Tigereye ST revascularization device and the Pantheris atherectomy device for removing plaque from peripheral arteries. The company also publishes educational content for clinicians and patients on topics such as the technical principles of PTA balloons, the development history of vascular stents, and the management of hemodialysis access. Zylox-Tonbridge has emphasized rapid commercial expansion. According to a company news item on its website, the approval for commercialization of multiple products enabled 544% year-on-year revenue growth for the company in 2021. The company maintains an investor relations section with announcements, circulars, prospectuses, financial reports, corporate information, presentation materials, and a financial calendar, indicating that it is a publicly listed entity. It is listed on the Hong Kong Stock Exchange under the ticker 2190.HK. Beyond its commercial activities, Zylox-Tonbridge publishes annual Environmental, Social, and Governance (ESG) reports and ESG stories, including patient stories such as "Bringing Hope to the Life of a Young Father After Stroke" and "'Her Power' Shines, Advancing with Zylox-Tonbridge towards Boundless Possibilities." The company also highlights green manufacturing initiatives, such as photovoltaic power support on its factory roofs. Its stated corporate values center on integrity and compliance, which it describes as "the core of our corporate values." The company operates as Zylox-Tonbridge Medical Group and presents itself as an international medical device company with a growing global footprint.

Zylox-Tonbridge Medical Technology Co., Ltd. is a medical device company headquartered in Hangzhou, Zhejiang Province, China. It operates as an international medical device group focused on neurovascular and peripheral vascular interventional devices. The company's official website presents it under the banner "Revascularization Device, International Medical Device Company | Zylox-Tonbridge Medical Group," reflecting its strategic focus on revascularization therapies for stroke and peripheral artery disease. The company built its business around two principal solution areas: Neurovascular Interventions and Vascular Interventions. Its neurovascular portfolio addresses conditions such as acute ischemic stroke, while its vascular portfolio addresses peripheral artery disease, hemodialysis access dysfunction, and related vascular conditions. Over time, the company expanded its product range to include stent retrievers, thrombectomy stents, PTA balloon catheters, atherectomy devices such as Pantheris, IVC filters, and vascular stents. A significant turning point came with the commercialization of multiple products. According to a company news item published on its website, the approval for commercialization of multiple products enabled 544% year-on-year revenue growth for the company in 2021. This rapid growth reflected the company's transition from a development-stage enterprise to a commercial-stage medical device manufacturer with a broad approved product portfolio. Zylox-Tonbridge is a publicly listed company. Its investor relations section includes announcements and circulars, prospectuses and financial reports, corporate information, presentation materials, and a financial calendar. The company is listed on the Hong Kong Stock Exchange under the stock code 2190.HK. Its public listing provided capital to support research and development, manufacturing expansion, and market development both in China and internationally. The company has also invested in corporate social responsibility and sustainability. It publishes annual Environmental, Social, and Governance (ESG) reports, including a 2024 ESG report and a 2025 ESG report, and shares ESG stories that highlight patient outcomes and community impact. Examples include "Bringing Hope to the Life of a Young Father After Stroke" and "'Her Power' Shines, Advancing with Zylox-Tonbridge towards Boundless Possibilities." The company also promotes green manufacturing, such as photovoltaic power support on its factory roofs. Its stated corporate values emphasize integrity and compliance, which it describes as "the core of our corporate values." Today, Zylox-Tonbridge operates as Zylox-Tonbridge Medical Group, an international medical device company with a portfolio spanning neurovascular and vascular interventions, a presence in the Chinese market, and aspirations in international markets. It continues to develop and commercialize minimally invasive devices aimed at improving outcomes for patients with vascular and neurovascular diseases.

• Approval for commercialization of multiple products enabled 544% year-on-year revenue growth for the company in 2021.

• Publication of the 2024 Environmental, Social, and Governance Report.

• Publication of the 2025 Environmental, Social, and Governance Report.

International medical device company focused on revascularization and minimally invasive vascular interventions.

• Tigereye ST revascularization device

  A revascularization device highlighted on the company's website with an explainer video.

• Pantheris atherectomy device

  An atherectomy device for removing plaque from peripheral artery disease.

• PTA balloon catheters

  Balloon catheters used in peripheral vascular treatment and hemodialysis access management.

• IVC filter device

  Inferior vena cava filter device for vascular interventions.

• Vascular stents

  Stents used in vascular interventions, including thrombectomy stents.

1. 1Revascularization Device, International Medical Device Company | Zylox-Tonbridge Medical Groupzyloxtb.com
2. 2Development History of Vascular Stents - ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD.zyloxtb.com
3. 3Zylox-Tonbridge: Approval for Commercialization of Multiple Products Enabled 544% Year-on-year Revenue Growth for the Company in 2021 - ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD.zyloxtb.com
4. 4About - ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD.zyloxtb.com
5. 5Zylox-Tonbridge Medical Technology Co., Ltd. (China) - Wikidatawikidata.org